Ramucirumab plus docetaxel improves progression-free survival in urothelial cancer
Ramucirumab plus docetaxel improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy, according to late-breaking results from the phase ...
Sep 11, 2017